Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242
Status:
Completed
Trial end date:
2021-03-11
Target enrollment:
Participant gender:
Summary
This is the first time HTL0014242 will be administered to humans. The principal aim of this
study is to obtain safety and tolerability data when HTL0014242 is administered orally as
single doses to healthy subjects. This information, together with the pharmacokinetics data,
will help establish the doses and dosing regimen suitable for future studies in patients